Search results
Results from the WOW.Com Content Network
Cipla has 34 manufacturing units in 8 locations across India and a presence in over 80 countries. [ 26 ] [ 27 ] Exports accounted for 48% ₹ 4,948 crore (equivalent to ₹ 84 billion or US$970 million in 2023) of its revenue for the 2013–14 fiscal year. [ 28 ]
Cipla, India's No.3 generic drugmaker by sales, reported a better-than-expected quarterly profit on Friday, boosted by strength in its key domestic and North American businesses. The results come ...
India's revenue from pharmaceutical exports was $25.3 billion in the 2022-2023 financial year. [7] In terms of the global market, India currently holds an accountable share and is known as the pharmacy of the world. [9] The country is the largest global supplier of generic medicine. [10] India produces more than 50% the world's vaccines. [11]
Aurobindo Pharma features among the top 10 companies in India in terms of consolidated revenues. [6] Aurobindo exports to over 125 countries with more than 70% of its revenues derived out of international operations. In 2014, Aurobindo purchased the generic operations of Actavis in 7 Western European countries for $41 million. [10] [11]
HYDERABAD/BENGALURU (Reuters) -Cipla, India's third-largest generics drugmaker by sales, beat first-quarter profit estimates on Friday as it reported higher sales in its North America market ...
BENGALURU (Reuters) -Indian drugmaker Cipla said on Friday its U.S. unit was recalling six batches of albuterol sulfate inhalation aerosol due to a "container defect". "The company is initiating a ...
Thakur left India for the United States and contacted the Food and Drug Administration (FDA), which started investigating his claims. [17] As a result, on 16 September 2008, the Food and Drug Administration issued two warning letters to Ranbaxy Laboratories Ltd. and an Import Alert for generic drugs produced by two manufacturing plants in India ...
Lupin's businesses encompass the entire pharmaceutical value chain, ranging from branded and generic formulations, APIs, advanced drug delivery systems to biotechnology. . The company's drugs reach 70 countries [22] with a footprint that covers advanced markets such as USA, Europe, Japan, [23] Australia as well as emerging markets including India, the Philippines and South Africa to name a